JP2015524422A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524422A5
JP2015524422A5 JP2015523550A JP2015523550A JP2015524422A5 JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5 JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5
Authority
JP
Japan
Prior art keywords
seq
set forth
polypeptide
sequence set
respect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015523550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065669 external-priority patent/WO2014016362A1/en
Publication of JP2015524422A publication Critical patent/JP2015524422A/ja
Publication of JP2015524422A5 publication Critical patent/JP2015524422A5/ja
Pending legal-status Critical Current

Links

JP2015523550A 2012-07-24 2013-07-24 ワクチン組成物 Pending JP2015524422A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305908 2012-07-24
EP12305908.1 2012-07-24
EP12305911.5 2012-07-25
EP12305911 2012-07-25
PCT/EP2013/065669 WO2014016362A1 (en) 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection

Publications (2)

Publication Number Publication Date
JP2015524422A JP2015524422A (ja) 2015-08-24
JP2015524422A5 true JP2015524422A5 (enExample) 2016-09-08

Family

ID=48856641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523550A Pending JP2015524422A (ja) 2012-07-24 2013-07-24 ワクチン組成物

Country Status (15)

Country Link
US (1) US20150265695A1 (enExample)
EP (1) EP2877207A1 (enExample)
JP (1) JP2015524422A (enExample)
KR (1) KR20150036593A (enExample)
CN (1) CN104812408A (enExample)
AU (1) AU2013295016A1 (enExample)
BR (1) BR112015001313A2 (enExample)
CA (1) CA2878599A1 (enExample)
GT (1) GT201500005A (enExample)
HK (1) HK1212905A1 (enExample)
MX (1) MX2015000446A (enExample)
PE (1) PE20150356A1 (enExample)
PH (1) PH12014502875A1 (enExample)
SG (1) SG11201500439RA (enExample)
WO (1) WO2014016362A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3166063A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
MY187896A (en) * 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CA2960102C (en) * 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
MX383329B (es) * 2014-12-22 2025-03-13 Merck Sharp & Dohme Llc Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
RS65084B1 (sr) * 2015-09-29 2024-02-29 Boehringer Ingelheim Animal Health Usa Inc Vakcine čestica sličnih virusu (vlp) parvovirusa pasa (cpv) i njihova upotreba
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
EP3730620A4 (en) 2017-12-21 2022-01-05 Green Biomed, Inc. CROSS-IMMUNIZING ANTIGEN VACCINE AND METHOD OF ITS MANUFACTURING
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
IL298307A (en) 2018-09-05 2023-01-01 Takeda Vaccines Inc Dengue fever vaccine unit dose and its administration
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CA3139328A1 (en) * 2019-05-15 2020-11-19 Codagenix Inc. Attenuated yellow fever virus and uses thereof for the treatment of cancer
CN120271718A (zh) * 2024-01-05 2025-07-08 北京昌平实验室 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP2002540171A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
CA2365411A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
EP1165130A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-3 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
IL147857A0 (en) * 1999-08-02 2002-08-14 American Cyanamid Co RESCUE OF MUMPS VIRUS FROM cDNA
US7094411B2 (en) 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
JP2005518332A (ja) 2001-05-23 2005-06-23 デンドレオン コーポレイション 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用
JP2005501532A (ja) 2001-06-01 2005-01-20 アカンビス インコーポレーティッド キメラフラビウイルスベクター
AU2002330672A1 (en) 2001-07-25 2003-02-17 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
HUE037330T2 (hu) * 2002-05-03 2018-08-28 The Government Of The Us Secretary Department Of Health And Human Services rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
CN1852734B (zh) * 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
JP5197362B2 (ja) * 2005-06-17 2013-05-15 サノフィ・パスツール デング熱セロタイプ１弱毒株
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
WO2009134717A1 (en) * 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN106421743A (zh) * 2009-07-29 2017-02-22 贝恩德·赫尔穆特·阿达姆·雷姆 聚合物微粒及其用途
US8900596B2 (en) * 2009-11-18 2014-12-02 The Board Of Regents Of The University Of Texas System Physicochemical (PCP) based consensus sequences and uses thereof
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
EP3932422A1 (en) * 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection

Similar Documents

Publication Publication Date Title
JP2015524422A5 (enExample)
CY1124202T1 (el) Εμβολια ανασυνδυασμενου zika
JP2014502156A5 (enExample)
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
JP2014000092A5 (enExample)
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
JP2017526689A5 (enExample)
JP2013517773A5 (enExample)
WO2017015463A3 (en) Infectious disease vaccines
JP2015524421A5 (enExample)
JP2015533841A5 (enExample)
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
JP2014534202A5 (enExample)
JP2014530010A5 (enExample)
JP2011530309A5 (enExample)
RU2015135890A (ru) Композиция вакцины
WO2010057159A3 (en) Antigens that elicit immune response against flavivirus and methods of using same
JP2016533332A5 (enExample)
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
JP2014507146A5 (enExample)